Replies to post #109897 on Biotech Values

[zipjet]

All told, EXEL strikes me as a company that’s desperately and prematurely trying to sell XL184 to the investment community as a cancer drug with Avastin-like upside. That could conceivably happen, but the odds are very much against it, IMO.

Well count me among those sold.

I question the degree to which supposedly independent clinicians participated in these investor-oriented events.

Listen to the presentation yesterday. Check out the named researchers who were on the panel (they are named in the slides) and tell me if they are hacks.

The researchers, when they saw the results, started looking for the errors. Bone mets don't just disappear. Could something be masking the damage?

Tumors shrink - so that could be true.

But the hemoglobin levels started rising.

And pain stopped like turning off a light switch.

XL 184 works in PC and perhaps beyond.

Is the effect durable? We don't know yet.

ij

[jq1234]

All told, EXEL strikes me as a company that’s desperately and prematurely trying to sell XL184 to the investment community as a cancer drug with Avastin-like upside. That could conceivably happen, but the odds are very much against it.

It depends on where you came from. I didn't get the impression they were trying to sell XL184 as a cancer drug with Avastin-like upside. XL184 was left to be dead after BMY walked, and now the RDT data showed great promise. I had low to moderate expectation on XL184 before RDT result. If I had worked on this study, I would be excited as well. Compare XL184 data in CRPC with Provenge and Abiraterone at the same stage, I like XL184's chance. The former showed almost no change to measurable disease, the later showed significantly reduction of PSA.

By the way, I don't even hold EXEL shares right now.